featured
Pembrolizumab in Patients With NSCLC of Performance Status 2
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab in Patients With Non-Small-Cell Lung Cancer of Performance Status 2 (PePS2): A Single-Arm, Phase 2 Trial
Lancet Respir Med 2020 Sep 01;8(9)895-904, G Middleton, K Brock, J Savage, R Mant, Y Summers, J Connibear, R Shah, C Ottensmeier, P Shaw, SM Lee, S Popat, C Barrie, G Barone, L BillinghamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.